Improved clinical outcome after invasive management of patients with recent myocardial infarction and proven myocardial viability: primary results of a randomized controlled trial (VIAMI-trial)

Table 5 Components of secondary endpoints and reasons for revascularization (conservative and nonviable group)*

	Conservative	Nonviable	p- value
	(n = 110)	(n = 75)
Angina (CCS)
I	71 (64.5%)	45 (60.0%)	0.54
II	22 (20%)	15 (20%)	0.54
III	11 (10%)	12 (16%)	0.54
IV	6 (5.5%)	3 (4.0%)	0.54
Total revascularizations	35 (31.8%)	25 (33.3%)	0.87
- Primary endpoint driven	9 (8.2%)	1 (1.3%)	0.05
- Abnormal predischarge X-ECG	5 (4.5%)	7 (9.3%)	0.23
- Stable angina with proven ischemia	10 (9.1%)	1 (1.3%)	0.03
- Miscellaneous or non-ischemic chest discomfort	11 (10.0%)	16 (21.3%)	0.02
PCI (before hospital discharge)	6 (5.5%)	7 (9.3%)	0.38
PCI (within one year)	20 (18.2%)	10 (13.3%)	0.42
CABG (before hospital discharge)	1 (1.0%)	2 (2.7%)	0.57
CABG (within one year)	8 (7.3%)	7 (9.3%)	0.78
TIMI flow culprit vessel (CAG)	2.16	2.45	0.41

* Differences between the treatment groups are expressed with a P-value. CAG = coronary angiography

ISSN: 1745-6215